Latest Pharma Insights
What’s Next? Five Things To Look Out For In August
Generics Bulletin previews the most noteworthy and anticipated events for August 2026.
Generics Bulletin - August 1, 2026
Generics Bulletin previews the most noteworthy and anticipated events for August 2026.
Generics Bulletin - August 1, 2026
Apnimed Rises On Its Public Debut As More Drug Developers Prepare IPO Launches
Apnimed’s initial public offering raised $192m to fund regulatory and commercial activities for its sleep apnea candidate Oxnimbi (AD109). Braveheart, Vogenx and Attovia are next in line for IPOs.
Scrip - August 1, 2026
Apnimed’s initial public offering raised $192m to fund regulatory and commercial activities for its sleep apnea candidate Oxnimbi (AD109). Braveheart, Vogenx and Attovia are next in line for IPOs.
Scrip - August 1, 2026
Apnimed Rises On Its Public Debut As More Drug Developers Prepare IPO Launches
Apnimed’s initial public offering raised $192m to fund regulatory and commercial activities for its sleep apnea candidate Oxnimbi (AD109). Braveheart, Vogenx and Attovia are next in line for IPOs.
Scrip - August 1, 2026
Apnimed’s initial public offering raised $192m to fund regulatory and commercial activities for its sleep apnea candidate Oxnimbi (AD109). Braveheart, Vogenx and Attovia are next in line for IPOs.
Scrip - August 1, 2026
Stryker Q2 Sales Rise To $6.59Bn As Cyberattack Recovery Takes Hold
Stryker's Q2 earnings showed strong recovery from a March cyberattack, with sales rising to $6.59bn and EPS of $3.30. The company narrowed full-year guidance upward and flagged robust second-half demand for capital and surgical robotics.
Medtech Insight - July 31, 2026
Stryker's Q2 earnings showed strong recovery from a March cyberattack, with sales rising to $6.59bn and EPS of $3.30. The company narrowed full-year guidance upward and flagged robust second-half demand for capital and surgical robotics.
Medtech Insight - July 31, 2026
Dexcom Lifts Full-Year Guidance, Looks Ahead To Mid-2027 Medicare Coverage Target
Dexcom lifted its full-year revenue guidance to $5.18bn–$5.25bn after a broad-based Q2 beat, with executives pointing to US patient growth, new international tenders and a Medicare expansion timeline targeting mid-2027.
Medtech Insight - July 31, 2026
Dexcom lifted its full-year revenue guidance to $5.18bn–$5.25bn after a broad-based Q2 beat, with executives pointing to US patient growth, new international tenders and a Medicare expansion timeline targeting mid-2027.
Medtech Insight - July 31, 2026
US Recovery, Emerging Market Gains, EU Troubles: Key Takeaways from Haleon’s Q2
Growth in key emerging markets like China and India propelled Haleon's sales growth in Q2. While the green shoots of recovery appeared in the US, challenging market conditions in Europe held back the world's largest consumer health company.
HBW Insight - July 31, 2026
Growth in key emerging markets like China and India propelled Haleon's sales growth in Q2. While the green shoots of recovery appeared in the US, challenging market conditions in Europe held back the world's largest consumer health company.
HBW Insight - July 31, 2026
What’s Next? Five Things To Look Out For In August
Generics Bulletin previews the most noteworthy and anticipated events for August 2026.
Generics Bulletin - August 1, 2026
Generics Bulletin previews the most noteworthy and anticipated events for August 2026.
Generics Bulletin - August 1, 2026
The Future of Surgery Is Here: How Medtronic Is Trading Surgical Gut Instinct For Data
Real-time recordings of surgical procedures, combined with edge-level AI analysis, are allowing Medtronic to transform the culture of surgery.
In Vivo - July 31, 2026
Real-time recordings of surgical procedures, combined with edge-level AI analysis, are allowing Medtronic to transform the culture of surgery.
In Vivo - July 31, 2026
Incannex Bets On Psychotherapy As The Missing Ingredient In Psychedelic Medicine
As President Trump's executive order on psychedelics reshapes the regulatory landscape, Incannex Healthcare says its insistence on guided psychotherapy – and a real-world clinic to prove the model works – gives it an edge rivals have ceded.
In Vivo - July 31, 2026
As President Trump's executive order on psychedelics reshapes the regulatory landscape, Incannex Healthcare says its insistence on guided psychotherapy – and a real-world clinic to prove the model works – gives it an edge rivals have ceded.
In Vivo - July 31, 2026